Navigation Links
Shell Transfers Its Codexis Shares to Raizen
Date:6/2/2011

REDWOOD CITY, Calif., June 2, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Equilon Enterprises LLC, a wholly owned subsidiary of Royal Dutch Shell plc, has completed the transfer of approximately 5.6 million shares of Codexis common stock (which represents approximately 15.7% of Codexis' total outstanding shares) to Raizen Energia Participacoes S.A., a Brazil-based biofuels joint venture between Shell and Cosan Limited.  This transfer occurred as part of the closing of the joint venture.  As a result of the share transfer, Raizen is now Codexis' largest stockholder, and, under an existing stockholder agreement, has the right to appoint a representative to Codexis' Board of Directors.

"We look forward to the opportunity to work with Raizen in development of biofuels," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.  "With access to feedstocks and experience in ethanol production, Raizen has the potential to accelerate future commercialization of renewable fuels."

About Raizen

Raizen is a $12 billion joint venture with annual production capacity of over 2 billion liters of ethanol, making it the third-largest fuels company in Brazil. It has a retail network of 4,500 fuel stations, 24 sugar mills and an installed capacity of 900MW of electric energy from sugar cane bagasse.

About Codexis

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and in carbon capture. Other potential markets include chemicals and water treatment. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the company's opportunities to develop biofuels with Raizen and Raizen's potential to accelerate future commercialization of renewable fuels. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Factors that could materially affect actual results include the timing, cost and feasibility of the production and commercialization of biofuels derived from cellulose.  Other factors can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:

Media:  Lyn Christenson, lyn.christenson@codexis.com, 650.421.8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212.827.3771
Investors:  Henk Adriaenssens, ir@codexis.com, 650.421.8331


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ben-Gurion U. research leads to improved calcium supplement derived from crustacean shells
2. UCSB physicists challenge classical world with quantum-mechanical implementation of shell game
3. First high-resolution images of bone, tooth and shell formation
4. Spherix Transfers Stock Listing to Nasdaq Capital Market
5. Codexis Reports First Quarter 2011 Results
6. Former Senator Byron Dorgan Elected to Codexis Board
7. Codexis Reports Fourth Quarter and Full Year 2010 Results
8. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
9. Codexis Names Vonnie Estes to New Technology Strategic Planning VP Role
10. Codexis R&D Productivity Panels Also Used By Roche
11. Codexis Names Lori Giver VP Systems Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... Atlanta, it seems everyone has a chance to express their ... expressive and dynamic community unlike any other. The businesses that ... With their newest salon in ... on that tradition with a unique, fresh approach to head ... the newest of 13 nationwide locations, each of them well-situated ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
Breaking Biology Technology:
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
(Date:1/26/2017)... 2017  Acuity Market Intelligence today released the ... Identity".  Acuity characterizes 2017 as a "breakout" year ... reflects a new understanding of the potential benefits ... digital identity are often perceived as threats to ... Principal of Acuity Market intelligence. "However, taken together ...
Breaking Biology News(10 mins):